Comparative Analysis of Oral Iron With Injectable Ferric Carboxymaltose for Post Partum Iron Deficiency Anaemia
Comparative Analysis of Oral Iron With Injectable Ferric Carboxymaltose for Treatment of Post Partum Iron Deficiency Anaemia
The aim of this open label, interventional, randomized controlled clinical trial is to compare the efficacy and safety of ferric carboxymaltose injection with oral iron in treatment of postpartum iron deficiency anaemia in postnatal women. Inclusion criteria:women within 10 days of delivery, Hb >7 gm/dl and ≤10 gm and peripheral smear showing microcytic hypochromic anaemia or red cell indices suggestive of iron deficiency anaemia or Mentzer index >13.
Primary outcome measures-rise in Hb from baseline to 4 and 6 weeks Secondary outcome measures-Percentage of patients achieving Hb >11 g/dl at 4 and 6 weeks.
Percentage of patients achieving Hb rise >3 g/dl from baseline at 4 and 6 weeks Change in red cell indices and peripheral smear from baseline to 6 weeks Side effects profile of injectable Ferric carboxymaltose injection and oral iron.
Researcher compares the efficacy and safety of ferric carboxymaltose with Oral iron in post partum iron deficiency anaemia Participant's detailed history, general physical and systemic examination was performed. CBC with red cell indices, reticulocyte counts, peripheral smear examination, serum Iron, Ferritin, Transferrin, TIBC levels and LFT were done.
Subjects were randomized in a 1:1 ratio into two groups: Group I (n=100) received intravenous ferric carboxymaltose and Group II (n=100) received oral ferrous Fumarate twice a day for 6 weeks.
All subjects were followed at 4 and 6 weeks. Repeat Hb estimation was done at 4 and 6 weeks while RBC indices and serum iron parameters were repeated at 6 weeks. Adverse effects were recorded.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Delhi, Índia, 110015
- ESI-PGIMSR, Basaidarapur
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Postnatal women within 10 days of delivery.
- Hb should be >7 gm/dl and ≤10 gm.
- Peripheral smear showing microcytic hypochromic anaemia or red cell indices suggestive of iron deficiency anaemia or Mentzer index >13.
Exclusion Criteria:
- 1. Puerperal pyrexia. 2. Known drug allergy or intolerance to iron therapy. 3. History of chronic medical illness. 4. Known cases of Thalassemia 5. Received other intervention for management of anaemia such as blood transfusion in last three months.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Group I: Ferric carboxymaltose (FCM)
FCM was given as slow intravenous infusion; maximum single dose not exceeding 15 mg/kg or 1000 mg/dose in 250 ml of 0.9% normal saline over 15 minutes During infusion, subject was kept under strict observation. FCM was repeated weekly up to calculated dose or maximum of 2500mg. Total dose of IV FCM was calculated by Ganzoni formula: - Total dose of iron = body weight (in kg) x (14-actual Hb) x 2.4 + 500 where, 14 is target Hb (g/dl), 2.4 unitless conversion constant, 500 is target iron store in mg |
FCM was given as slow intravenous infusion; maximum single dose not exceeding 15 mg/kg or 1000 mg/dose in 250 ml of 0.9% normal saline over 15 minutes.
FCM was repeated weekly up to calculated dose or maximum of 2500mg.
|
|
Comparador Ativo: Group II : Oral Iron
Second group of subjects were instructed to take oral iron (ferrous fumarate tablet containing 112 mg elemental iron) 2 times daily 1 hour before meals for 6 weeks.
|
FCM was given as slow intravenous infusion; maximum single dose not exceeding 15 mg/kg or 1000 mg/dose in 250 ml of 0.9% normal saline over 15 minutes.
FCM was repeated weekly up to calculated dose or maximum of 2500mg.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean increase in haemoglobin at 4 weeks and 6 weeks in Group I versus Group II
Prazo: Haemoglobin measurement at baseline, 4 week post treatment and 6 week post FCM intervention or adequate oral treatment
|
The mean change in haemoglobin was measured at 4 weeks and 6 weeks post intervention in parenteral and oral group.
|
Haemoglobin measurement at baseline, 4 week post treatment and 6 week post FCM intervention or adequate oral treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Anaemia correction(Hb >11 gm/dl), from baseline at 4 and 6 weeks in group I versus Group II
Prazo: Anaemia correction (Hb>11gm/dl) at 4 week and 6 week post FCM intervention or adequate oral treatment
|
Percentage of women in the parenteral group as compared to oral group who achieved correction of anaemia i.e.
Hb >11gm/dl at 4 and 6 weeks post intervention.
|
Anaemia correction (Hb>11gm/dl) at 4 week and 6 week post FCM intervention or adequate oral treatment
|
|
Haemoglobin (Hb) rise> 3gm/dl from baseline at 4 and 6 weeks in group I versus Group II
Prazo: Hb rise> 3 gm/dl at 4 week and 6 week post FCM intervention or adequate oral treatment
|
Women in the parenteral group as compared to oral group who achieved Haemoglobin rise of >3gm/dl at 4 and 6 weeks post intervention.
|
Hb rise> 3 gm/dl at 4 week and 6 week post FCM intervention or adequate oral treatment
|
|
Haemoglobin (Hb) rise>2gm from baseline at 4 and 6 weeks in group I versus Group II
Prazo: Hb rise>2gm/dl at 4 week and 6 week post FCM intervention or adequate oral treatment
|
Women in the parenteral group as compared to oral group who achieved haemoglobin (Hb) rise>2gm from baseline at 4 week and 6 week post intervention.
|
Hb rise>2gm/dl at 4 week and 6 week post FCM intervention or adequate oral treatment
|
|
Change in red cell indices and peripheral smear from baseline to 6 weeks
Prazo: Change in red cell indices and peripheral smear at baseline and 6 week post FCM intervention or adequate oral treatment
|
To record changes in all the haematological parameters from baseline to 6 weeks post intervention both parenteral and oral groups.
|
Change in red cell indices and peripheral smear at baseline and 6 week post FCM intervention or adequate oral treatment
|
|
Side effects profile for participants of Group I and II
Prazo: Side effects observed in participants receiving Group I and Group II treatment upto 6 weeks post intervention..
|
To record the side effect profile in participants of parenteral and oral group in order to determine safety of the intervention upto 6 weeks post intervention.
|
Side effects observed in participants receiving Group I and Group II treatment upto 6 weeks post intervention..
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Shreya Mahajan, MBBS, Post graduate resident, Department of OBG, ESI-PGIMSR, Basaidarapur,Delhi
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ESIPGIMSR-IEC/2024031
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Ferric Carboxymaltose (FCM)
-
Vifor PharmaICON Clinical Research; American Regent, Inc.ConcluídoDoença Renal Crônica | Anemia ferroprivaReino Unido, Estados Unidos, Austrália, Áustria, Bélgica, República Checa, Dinamarca, França, Alemanha, Grécia, Itália, Holanda, Noruega, Polônia, Portugal, Romênia, Espanha, Suécia, Peru
-
American Regent, Inc.RescindidoSíndrome das Pernas Inquietas (SPI)Estados Unidos
-
Ziekenhuis Oost-LimburgFederal Knowledge Centre (KCE)RecrutamentoHipertensão pulmonar | Falta de ferroBélgica
-
Shahida Islam Medical ComplexConcluídoAnemia pós -partoPaquistão
-
Fuda Cancer Hospital, GuangzhouConcluídoCélulas Neoplásicas CirculantesChina
-
Fuda Cancer Hospital, GuangzhouConcluídoCélulas Neoplásicas CirculantesChina
-
Herzzentrum BremenRetiradoTreino de exercícios | Insuficiência Cardíaca com Fração de Ejeção Reduzida | Carboximaltose FérricaAlemanha
-
Fuda Cancer Hospital, GuangzhouConcluídoCélulas Neoplásicas CirculantesChina
-
Fuda Cancer Hospital, GuangzhouConcluídoCélulas Neoplásicas CirculantesChina
-
Fuda Cancer Hospital, GuangzhouConcluídoCélulas Neoplásicas CirculantesChina